KBY Biotech Indexv0.0.34
Search
← Pipeline|Pemiratamab

Pemiratamab

Phase 2/3
SPR-9653
By ARS Pharma
Source: Trial-derived·Trials: 2
Modality
siRNA
MOA
RAS(ON)i
Target
TYK2
Pathway
Cell Cycle
WMIPFPompe
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
~Oct 2021
→ ~Jan 2023
Phase 2
Apr 2023
→ Feb 2027
Phase 2Current
NCT08432617
620 pts·IPF
2024-05→2027-02·Completed
NCT05509975
821 pts·Pompe
2023-04→TBD·Recruiting
1,441 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-0210mo awayPh3 Readout· IPF
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Recruit…
P2/3
Complet…
Catalysts
Ph3 Readout
2027-02-02 · 10mo away
IPF
RecruitingCompleted|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT08432617Phase 2/3IPFCompleted620Mayo
NCT05509975Phase 2/3PompeRecruiting821Biomarker
Competitors (10)
DrugCompanyPhaseTargetMOA
VoxacilimabPfizerPhase 2TYK2CAR-T BCMA
MRK-3732Merck & CoPhase 1TYK2PARPi
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
COR-9566CorceptApprovedTYK2HPK1i
SND-9531SyndaxPhase 3TYK2AuroraAi